IP Library Granted Patent US 11,154,041
Granted Patent B2
US 11,154,041 · App. 17/010,054 · Granted Oct 26, 2021

Genetically modified non-human animal with human or chimeric genes

Inventors: Yuelei Shen (Beijing, CN); Yanan Guo (Beijing, CN); Yang Bai (Beijing, CN); Rui Huang (Beijing, CN); Xiaofei Zhou (Beijing, CN); Chengzhang Shang (Beijing, CN); Meiling Zhang (Beijing, CN); Jiawei Yao (Beijing, CN); Chaoshe Guo (Beijing, CN)
Assignees: Biocytogen Pharmaceuticals (Beijing) Co., Ltd.; Biocytogen JiangSu Co., Ltd.
A01K67/0278C07K14/7155C12N15/8509A01K2217/072A01K2227/105C12N2015/8527
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,154,041
App. No.
17/010,054
Granted
Oct 26, 2021
Kind
B2
Abstract

The present disclosure relates to genetically modified non-human animals that express a human or chimeric (e.g., humanized) IL4R and/or IL4, and methods of use thereof.

Claims (19)

1. A genetically-modified rodent whose genome comprises a replacement of an endogenous gene sequence encoding the extracellular region of endogenous IL4R protein with a human gene sequence encoding the extracellular region of human IL4R protein, forming a chimeric IL4R gene sequence, wherein the chimeric IL4R gene sequence is operably linked to an endogenous regulatory element of the rodent, wherein the rodent detectably expresses a functional chimeric IL4R protein on the surface of an activated T cell of the rodent, wherein the chimeric IL4R protein comprises an amino acid sequence that is at least 90% identical to SEQ ID NO: 44, wherein the chimeric IL4R protein comprises an endogenous signal peptide.

2. The rodent of claim 1 , wherein the chimeric IL4R protein comprises an amino acid sequence that is identical to SEQ ID NO: 44.

3. The rodent of claim 1 , wherein the chimeric IL4R protein consists of an amino acid sequence that is identical to SEQ ID NO: 44.

4. The rodent of claim 1 , wherein the rodent is a mouse.

5. The rodent of claim 1 , wherein the rodent does not express endogenous IL4R protein.

6. The rodent of claim 1 , wherein the rodent further comprises a sequence encoding a human or chimeric IL4 protein.

7. The rodent of claim 1 , whose genome further comprises at least one chromosome comprising a sequence encoding a human IL4 protein, wherein the sequence is operably linked to:

1) a human regulatory element at an endogenous IL4 gene locus in the at least one chromosome; or

2) an endogenous regulatory element and an endogenous 3′ UTR at an endogenous IL4 gene locus in the at least one chromosome.

8. The rodent of claim 7 , wherein the sequence encoding the human IL4 protein is operably linked to a human regulatory element at the endogenous IL4 gene locus in the at least one chromosome, and the human regulatory element comprises a 5′ UTR of human IL4 gene.

9. The rodent of claim 7 , wherein the rodent is a mouse.

10. The rodent of claim 7 , wherein the rodent does not express endogenous IL4 protein.

11. The rodent of claim 7 , wherein the sequence encoding the human IL4 protein is operably linked to a human regulatory element at an endogenous IL4 gene locus in the at least one chromosome.

12. The rodent of claim 7 , wherein the sequence encoding the human IL4 protein is operably linked to an endogenous regulatory element and an endogenous 3′ UTR at an endogenous IL4 gene locus in the at least one chromosome.

13. The rodent of claim 1 , wherein the chimeric IL4R protein comprises an amino acid sequence that is at least 95% identical to SEQ ID NO: 44.

14. A genetically-modified rodent whose genome comprises a replacement of an endogenous IL4R gene sequence encoding a portion of the extracellular region of endogenous IL4R protein with a human IL4R gene sequence encoding a corresponding portion of the extracellular region of human IL4R protein, wherein the human IL4R gene sequence is operably linked to an endogenous regulatory element to the rodent thereby forming a chimeric IL4R gene, wherein the rodent detectably expresses a functional chimeric IL4R protein on the surface of an activated T cell of the rodent, wherein the chimeric IL4R protein comprises an amino acid sequence that is at least 90% identical to SEQ ID NO: 44, wherein the chimeric IL4R protein comprises an endogenous signal peptide.

15. The rodent of claim 14 , wherein the chimeric IL4R protein comprises an amino acid sequence that is 95% identical to SEQ ID NO: 44.

16. The rodent of claim 14 , wherein the rodent is a mouse.

17. The rodent of claim 14 , wherein the rodent further comprises a sequence encoding a human or chimeric IL4 protein.

Assignments (2)
CHANGE OF NAME Recorded Jan 22, 2021
From: BEIJING BIOCYTOGEN CO., LTD
To: BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO., LTD.
Reel/Frame 055087/0015 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 4, 2020
From: SHEN, YUELEI; GUO, YANAN; BAI, YANG; HUANG, RUI; ZHOU, XIAOFEI; SHANG, CHENGZHANG; ZHANG, MEILING; YAO, JIAWEI; GUO, CHAOSHE
To: BEIJING BIOCYTOGEN CO., LTD; BIOCYTOGEN JIANGSU CO.,LTD.
Reel/Frame 053696/0133 →
Priority Claims (2)
CN 201811194052.1 · Oct 12, 2018 · national
CN 201811628008.7 · Dec 28, 2018 · national
Continuity (2)
Continuation PCTCN2019110819 · Oct 12, 2019
Related Publication 20210045367A1 · Feb 18, 2021